Earnings Preview: 3M, JNJ, Travelers, and P&G Set to Report This Week
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
- 3M Earnings Miss: 3M reported earnings on Tuesday, missing revenue expectations while beating EPS estimates, resulting in a 7.8% drop in stock price to $155.84, marking the first revenue miss after ten consecutive quarters of EPS beats, indicating challenges in the macro environment.
- Strong Expectations for J&J: Johnson & Johnson is expected to report Q4 EPS of $2.48 and revenue of $24.15 billion, both higher than last year, with a track record of beating revenue estimates in nine of the last ten quarters, showcasing strategic adjustments to mitigate patent expiration risks.
- Travelers' Performance Outlook: Travelers anticipates Q4 EPS of $8.60 and revenue of $11.65 billion, down from last year, yet has exceeded revenue estimates in nine of the last ten quarters, reflecting stability in the insurance market.
- P&G's Future Prospects: Procter & Gamble expects Q2 EPS of $1.87 and revenue of $22.27 billion, slightly down in EPS but with a strong history of beating revenue estimates in six of the last eleven quarters, demonstrating resilience in the consumer goods sector.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 218.660
Low
190.00
Averages
218.50
High
240.00
Current: 218.660
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
